Kala Pharmaceuticals, Inc. (KALA)
KALA moved a median of +0.41% 30 minutes after news, and -0.13% by the close. How KALA actually reacts to news — the realized, point-in-time move the market made, measured across 248 labeled events over the last three years with zero look-ahead.
KALA’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 44% | 216 |
| 30-min | +0.41% | 56% | 236 |
| 60-min | +0.15% | 52% | 247 |
| to close | -0.13% | 47% | 247 |
| Middle 50% of KALA reactions | -1.26% to +2.51% |
|---|---|
| Median reaction (30-min) | +0.41% |
| Measured reactions | 248 |
Half of all Kala Pharmaceuticals, Inc. news events land between -1.26% and +2.51% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when KALA moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to KALA's baseline. Nothing else.
Recent KALA events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form DEF 14A KALA BIO, Inc. For: Nov 03 | SEC filing · Form DEF | SEC EDGAR | +0.73% | -12.89% | |
| Kala Bio and Virotek Sign Letter of Intent with U.S. DNA Testing Platform to Resell Virotek's Suite of Genetic Testing Products | Press release | GlobeNewswire | +0.00% | +5.46% | |
| KALA BIO Adds Healthcare Operator Yenvy Truong to Advisory Team | Press release | GlobeNewswire | -3.36% | +1.00% | |
| Form PRE 14A KALA BIO, Inc. For: Sep 11 | SEC filing · Form PRE | SEC EDGAR | -0.29% | -6.78% | |
| Form 8-K KALA BIO, Inc. For: Sep 03 | SEC filing · Form 8-K | SEC EDGAR | -1.99% | -3.31% | |
| Form 8-K KALA BIO, Inc. For: Sep 09 | SEC filing · Form 8-K | SEC EDGAR | +0.04% | +0.52% | |
| Kala Bio and Virotek Finalize Definitive Agreement Establishing Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program | Press release | GlobeNewswire | -1.33% | +6.43% | |
| Kala Bio and Virotek Announce Letter of Intent to Establish an Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program | Press release | GlobeNewswire | -0.50% | +1.92% | |
| Form 8-K KALA BIO, Inc. For: Aug 27 | SEC filing · Form 8-K | SEC EDGAR | -0.35% | -16.15% | |
| Form 10-Q KALA BIO, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -10.53% | |
| Form NT 10-Q KALA BIO, Inc. For: Jun 30 | SEC filing · Form NT | SEC EDGAR | -3.33% | +3.01% | |
| Form 8-K KALA BIO, Inc. For: Jul 22 | SEC filing · Form 8-K | SEC EDGAR | -4.19% | -16.74% | |
| Form EFFECT KALA BIO, Inc. | SEC filing · Form EFFECT | SEC EDGAR | -0.39% | -2.33% | |
| Form S-3/A KALA BIO, Inc. | SEC filing · Form S-3 | SEC EDGAR | -1.12% | -1.49% | |
| Form 10-Q KALA BIO, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.17% | -1.01% | |
| Form 8-K KALA BIO, Inc. For: May 07 | SEC filing · Form 8-K | SEC EDGAR | -5.57% | -4.00% | |
| Form S-3 KALA BIO, Inc. | SEC filing · Form S-3 | SEC EDGAR | -5.57% | -4.00% | |
| KALA BIO Announces Reverse Stock Split | Press release | GlobeNewswire | -2.37% | -6.42% | |
| Kala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic Medicine | Press release | GlobeNewswire | -0.65% | -7.45% | |
| Form 10-K KALA BIO, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -4.13% | -3.87% | |
| Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development Opportunities | Press release | GlobeNewswire | +8.33% | -9.44% | |
| Form NT 10-K KALA BIO, Inc. For: Dec 31 | SEC filing · Form NT | SEC EDGAR | +8.33% | -9.44% | |
| KALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now Live | Press release | GlobeNewswire | +0.33% | -5.00% | |
| Red Light Holland Engages Kala Bio’s Researgency.AI Platform to Support Clinical Development of Filament’s Patented PEX010 Botanical Psilocybin Drug Candidate | Press release | GlobeNewswire | -2.76% | +2.52% | |
| Form D KALA BIO, Inc. | SEC filing · Form D | SEC EDGAR | -2.76% | +2.52% | |
| Kala Bio Launches a Revolution for Biotech- First AI Agent Deploying in 14 Days as $180 Billion Agentic AI Healthcare Revolution Accelerates | Press release | GlobeNewswire | +8.69% | -18.91% | |
| Form 8-K KALA BIO, Inc. For: Mar 03 | SEC filing · Form 8-K | SEC EDGAR | +1.56% | -3.90% | |
| KALA BIO Announces Strategic Initiative to Deploy and Continue to Develop an On-Premises AI Infrastructure Platform for the Biotech Industry; Enters Into Platform Development and Exclusive License Agreement for Proprietary AI Research Platform “Researgenc | Press release | GlobeNewswire | +1.56% | -3.90% | |
| Form 8-K KALA BIO, Inc. For: Feb 16 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -7.17% | |
| Form EFFECT KALA BIO, Inc. | SEC filing · Form EFFECT | SEC EDGAR | +4.29% | -3.55% | |
| Form D KALA BIO, Inc. | SEC filing · Form D | SEC EDGAR | +4.60% | +11.37% | |
| Form S-3 KALA BIO, Inc. | SEC filing · Form S-3 | SEC EDGAR | +1.54% | +6.24% | |
| Form 8-K KALA BIO, Inc. For: Feb 02 | SEC filing · Form 8-K | SEC EDGAR | +2.94% | +6.18% | |
| Form 8-K KALA BIO, Inc. For: Jan 30 | SEC filing · Form 8-K | SEC EDGAR | +3.03% | +4.52% | |
| Form DEFA14A KALA BIO, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +1.67% | +5.28% | |
| Form 8-K KALA BIO, Inc. For: Jan 20 | SEC filing · Form 8-K | SEC EDGAR | -0.47% | -3.02% | |
| Form 8-K KALA BIO, Inc. For: Jan 08 | SEC filing · Form 8-K | SEC EDGAR | -1.90% | +0.77% | |
| Form 8-K KALA BIO, Inc. For: Dec 30 | SEC filing · Form 8-K | SEC EDGAR | +1.04% | -1.72% | |
| Form DEFA14A KALA BIO, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +0.47% | +4.40% | |
| KALA BIO Settles Approximately $10.6 million of Debt | Press release | GlobeNewswire | +1.04% | -1.72% | |
| Form 8-K KALA BIO, Inc. For: Dec 26 | SEC filing · Form 8-K | SEC EDGAR | -1.32% | -2.30% | |
| Form DEF 14A KALA BIO, Inc. For: Jan 30 | SEC filing · Form DEF | SEC EDGAR | +4.61% | +4.69% | |
| Form 8-K KALA BIO, Inc. For: Dec 19 | SEC filing · Form 8-K | SEC EDGAR | -3.53% | -7.03% | |
| Form PRER14A KALA BIO, Inc. | SEC filing · Form PRER14A | SEC EDGAR | -2.69% | -5.08% | |
| Form 8-K KALA BIO, Inc. For: Dec 15 | SEC filing · Form 8-K | SEC EDGAR | -0.54% | -1.51% | |
| Form 8-K KALA BIO, Inc. For: Dec 16 | SEC filing · Form 8-K | SEC EDGAR | -4.31% | -8.90% | |
| Form 8-K KALA BIO, Inc. For: Dec 04 | SEC filing · Form 8-K | SEC EDGAR | -1.20% | -1.38% | |
| KALA BIO Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules | Press release | GlobeNewswire | -0.01% | -1.11% | |
| KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules | Press release | GlobeNewswire | -9.93% | -20.95% | |
| KALA BIO Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar | Press release | GlobeNewswire | +3.46% | +2.31% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the KALA section they belong to.
Where else KALA is measured.
KALA earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Cytosorbents Corporation (CTSO) | 249 | 0.00% | 49% |
| IRIDEX Corporation (IRIX) | 248 | +0.11% | 52% |
| MELINTA THERAPEUTICS INC (MLNT) | 248 | -0.38% | 34% |
| Heron Therapeutics, Inc. (HRTX) | 247 | -0.34% | 42% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Kala Pharmaceuticals, Inc.'s median reaction calculated?
Every labeled KALA news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 248 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 56% of KALA's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does KALA's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.